Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 4/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.56 |
| ▸ | CXCR3 | P49682 | 5/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.45 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5690806 | 0.89 | TMEM97 (0.59) | TMEM97SIGMAR1CXCR3KMT2ANPC1 | |
| SCHEMBL5690023 | 0.85 | TMEM97 (0.60) | TMEM97SIGMAR1CXCR3KMT2ANPC1 | |
| SCHEMBL5450120 | 0.84 | TMEM97 (0.57) | TMEM97SIGMAR1CXCR3KMT2ANPC1 | |
| SCHEMBL5861502 | 0.83 | TMEM97 (0.58) | TMEM97SIGMAR1CXCR3KMT2AKCNQ2 | |
| SCHEMBL5690040 | 0.83 | ERCC1 (0.58) | TMEM97SIGMAR1CXCR3LMNADRD2 | |
| SCHEMBL5861658 | 0.82 | MAPT (0.60) | TMEM97SIGMAR1CXCR3KMT2ANPC1 | |
| SCHEMBL5689952 | 0.80 | CXCR3 (0.57) | TMEM97SIGMAR1CXCR3KMT2ALMNA | |
| SCHEMBL5860142 | 0.80 | CXCR3 (0.60) | TMEM97SIGMAR1CXCR3 | |
| SCHEMBL5861550 | 0.76 | TMEM97 (0.59) | TMEM97SIGMAR1CXCR3DRD2 | |
| SCHEMBL5446306 | 0.76 | TMEM97 (0.67) | TMEM97SIGMAR1CXCR3NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7101881-B2 | Tetrahydroquinolines | PFIZER INC (US) | 2006-09-05 | — | — | US | claimed |
| EP-1641760-A2 | NOVEL TETRAHYDROQUINOLINES | Pfizer Products Inc. (US) | 2006-04-05 | — | — | EP | claimed |
| WO-2004108682-A2 | TETRAHYDROISOQUINOLINES AS ANTAGONISTS OF THE 5HT1B RECEPTOR | PFIZER PRODUCTS INC. (US) | 2004-12-16 | — | — | WO | claimed |
| US-20040254193-A1 | Novel tetrahydroquinolines | PFIZER INC | 2004-12-16 | — | — | US | claimed |
| US-7101881-B2 | Tetrahydroquinolines | PFIZER INC (US) | 2006-09-05 | — | — | US | disclosed |
| EP-1641760-A2 | NOVEL TETRAHYDROQUINOLINES | Pfizer Products Inc. (US) | 2006-04-05 | — | — | EP | disclosed |
| WO-2004108682-A2 | TETRAHYDROISOQUINOLINES AS ANTAGONISTS OF THE 5HT1B RECEPTOR | PFIZER PRODUCTS INC. (US) | 2004-12-16 | — | — | WO | disclosed |
| US-20040254193-A1 | Novel tetrahydroquinolines | PFIZER INC | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254193-A1 | Novel tetrahydroquinolines | HTR5A, SLC18A2, HTR3B | TMEM97 264/4885SIGMAR1 545/4885CXCR3 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.